Who are Ascelia's investors?

Ascelia's investors include Sunstone Capital.

Where is Ascelia headquartered?

Ascelia is headquartered in Malmö, SE.

Ascelia

Malmö, SE · Founded 2000 · 14 employees on LinkedIn · 1 known investors

Find your way into Ascelia

Paths you didn't know you had: your email and LinkedIn already hold routes to the Ascelia team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Ascelia Pharma is a biotech company developing and commercializing drugs for rare, orphan oncology-related conditions with unmet medical needs. Its clinical-stage pipeline includes Orviglance, an oral MRI contrast agent for detecting liver lesions, and Oncoral, an oral chemotherapy tablet for gastric cancer.

Biotech Healthtech Medical Devices

Founders & leadership

Magnus CorfitzenChief Executive OfficerMagnus Corfitzen has more than 20 years of experience in life sciences, having held operational and investment roles at biotech and medtech companies, served on the boards of 12 life science firms, and been involved in financing and business development transactions. He is Chief Executive Officer of Ascelia Pharma, a biotech company developing oral drugs for rare oncology conditions.

Andreas NorlinChief Scientific OfficerAndreas Norlin brings more than 20 years of experience in drug development across academia, biotech, and pharmaceutical companies, with expertise spanning preclinical and clinical development, regulatory affairs, and R&D management. His background encompasses project leadership, portfolio management, and cross-functional collaboration in the fields of diabetes, inflammatory disease, and drug delivery technologies.

Jennie WilborgssonChief Operating OfficerJennie Wilborgsson has over 15 years of experience in clinical drug development across Phase I–IV trials, with background in both sponsor and contract research organization roles, and has led clinical development teams managing multiple pipeline projects.

Anton HanssonChief Financial Officer

Investors · 1

Sunstone Capitallisted by Sunstone CapitalFrederiksberg

How we know: Sunstone Capital's portfolio page · the VCSheet dataset · Not right? Tell us

Funding

SEC filings, press & company announcements

Undisclosed amountDirected Share IssueApr 2026
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Ascelia Pharma Announces FDA Has Scheduled Type A Meeting for Orviglance NDA on September 9, 2026 - BioSpacebiospace.com · Aug 2026

Ascelia Pharma: Published FDA letter raises the odds of a more demanding path for Orviglance - Inderesinderes.se · Jul 2026

Frequently asked questions

What does Ascelia do?: Ascelia Pharma is a biotech company developing and commercializing drugs for rare, orphan oncology-related conditions with unmet medical needs. Its clinical-stage pipeline includes Orviglance, an oral MRI contrast agent for detecting liver lesions, and Oncoral, an oral chemotherapy tablet for gastric cancer.
Who are Ascelia's investors?: Ascelia's investors include Sunstone Capital.
Where is Ascelia headquartered?: Ascelia is headquartered in Malmö, SE.